Phaseline

Targets › EPOR

EPOR (Erythropoietin receptor): drug programs, companies and trials

13 programs from 12 companies in 24 trials: 11 Phase 3, 5 Phase 2, 5 Phase 4, 3 Phase 1; Hematology, Genitourinary, Other; next expected readout Dec 2026.

Receptor for erythropoietin, which mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade (By similarity). (UniProt, P19235)

Open in Phaseline: the race on EPOR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of Dalian Medical UniversityPegmolesatide
Continuous erythropoietin receptor activator (CERA)
EPORPhase 4Renal Anemia in Non-dialysis Chronic Kidney DiseaseDec 2026
Copenhagen University Hospital, RigshospitaletDarbepoetin alfa
Erythropoietin receptor agonist
EPORPhase 4Infective Endocarditis (IE)Apr 2028
Gangnam Severance Hospitaldarbepoetin alfa
Erythropoietin receptor agonist
EPORPhase 4Chronic Kidney Disease–
Fundacion Clinic per a la Recerca BiomédicaDarbepoetin Alfa
Erythropoietin receptor agonist
EPORPhase 3Liver Transplant; ComplicationsDec 2026
GenexineEfepoetin Alfa
Erythropoietin receptor agonist
EPORPhase 3Anemia of Chronic Kidney DiseaseJun 2027
BiocadBCD-131 (pegdarbepoetin beta)
Erythropoietin receptor (EPOR) agonist; pegylated darbepoetin beta
EPORPhase 3AnemiaOct 2027
TakedaElritercept
Erythropoietin receptor agonist
EPORPhase 3Myelodysplastic Syndromes; Myelodysplastic Syndrome; MyelofibrosisFeb 2028
Incepta PharmaceuticalsEpoetin Alfa
Erythropoietin receptor agonist
EPORPhase 3Healthy; Hypobaric Hypoxia; Anemia; Encephalopathy …–
University of WashingtonDarbepoetin Alfa
Erythropoietin receptor agonist
EPORPhase 2PrematurityJan 2027
TakedaTAK-226
Erythropoietin receptor agonist
EPORPhase 2Myelodysplastic SyndromesJun 2028
Yale UniversityDarbepoetin alfa
Erythropoietin receptor agonist
EPORPhase 2MDS (Myelodysplastic Syndrome)Aug 2030
Johns Hopkins UniversityErythropoietin (EPO)
Erythropoietin receptor agonist; promotes neuroprotection and neuro-repair
EPORPhase 1Intraventricular Hemorrhage of PrematuritySep 2027
H. Lee Moffitt Cancer Center and Research InstituteDarbepoetin Alfa
Erythropoietin receptor agonist
EPORPhase 1Myelodysplastic Syndromes–

Conditions

Myelodysplastic Syndromes (5) Anemia (3) Myelofibrosis (2) Anemia of Chronic Kidney Disease (1) Prematurity (1) Renal Anemia in Non-dialysis Chronic Kidney Disease (1) Myelodysplastic Syndrome (1) Chronic Kidney Disease (1) Intraventricular Hemorrhage of Prematurity (1) Liver Transplant; Complications (1) MDS (Myelodysplastic Syndrome) (1) Infective Endocarditis (IE) (1)

Modalities

protein or peptide (6), mixed (3), antibody (2), small molecule (1)

Companies

Takeda (2) Genexine (1) University of Washington (1) The First Affiliated Hospital of Dalian Medical University (1) Gangnam Severance Hospital (1) Johns Hopkins University (1) Biocad (1) Fundacion Clinic per a la Recerca Biomédica (1) H. Lee Moffitt Cancer Center and Research Institute (1) Yale University (1) Copenhagen University Hospital, Rigshospitalet (1) Incepta Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.